Breaking Barriers: Safely Targeting Obstructive Hypertrophic Cardiomyopathy at the Source : Episode 2
Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.
EP: 1.Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause
Now Viewing
EP: 2.Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
EP: 3.Aligning With 2023 ESC Guidelines in oHCM Treatment
EP: 4.Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes
EP: 5.Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice
- What have we learned from clinical trials evaluating CMI’s for oHCM? Hutt et al 2024
- Mavacamten: Outcomes; focused on feel and function Olivotto et al 2020, Maron et al 2023
- Longer-term outcomes of the VALOR-HCM RCT Desai et al 2023
- MAVA-LTE
- Aficamten: phase 2 REDWOOD-HCM soon to be completed, phase 3 trial SEQUIOA-HCM. Masri et al 2022, Maron et al 2023
Related Videos
Related Content
